These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23186108)

  • 1. Profound tumor-specific Th2 bias in patients with malignant glioma.
    Shimato S; Maier LM; Maier R; Bruce JN; Anderson RC; Anderson DE
    BMC Cancer; 2012 Nov; 12():561. PubMed ID: 23186108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.
    Shimato S; Natsume A; Wakabayashi T; Tsujimura K; Nakahara N; Ishii J; Ito M; Akatsuka Y; Kuzushima K; Yoshida J
    J Neurosurg; 2008 Jul; 109(1):117-22. PubMed ID: 18590440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
    Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
    Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
    Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
    J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
    Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
    Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
    Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
    Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
    Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
    Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
    Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
    Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
    BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.
    Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H
    J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas.
    Wu AH; Xiao J; Anker L; Hall WA; Gregerson DS; Cavenee WK; Chen W; Low WC
    J Neurooncol; 2006 Jan; 76(1):23-30. PubMed ID: 16155724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dentritic cells pulsed with HLA-A2-restricted MAGE-A1 peptide to generate cytotoxic T lymphocytes against malignant glioma.
    Shi H; Jiang X; Fu P; Zhou Y; Lu X
    J Huazhong Univ Sci Technolog Med Sci; 2010 Oct; 30(5):678-82. PubMed ID: 21063856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
    Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
    Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.
    Liu Z; Poiret T; Persson O; Meng Q; Rane L; Bartek J; Karbach J; Altmannsberger HM; Illies C; Luo X; Harvey-Peredo I; Jäger E; Dodoo E; Maeurer M
    Cancer Immunol Immunother; 2018 Feb; 67(2):237-246. PubMed ID: 29058035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma.
    Wu ZB; Qiu C; Zhang AL; Cai L; Lin SJ; Yao Y; Tang QS; Xu M; Hua W; Chu YW; Mao Y; Zhu JH; Xu J; Zhou LF
    J Immunol Res; 2014; 2014():131494. PubMed ID: 25126583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
    Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
    Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.